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The TCF-1 and LEF-1 transcription factors are known
to play critical roles in normal thymocyte develop-
ment. Unexpectedly, we found that TCF-1-deficient
(Tcf7/) mice developed aggressive T cell malig-
nancy, resembling human T cell acute lymphoblastic
leukemia (T-ALL). LEF-1 was aberrantly up-
regulated in premalignant Tcf7/ early thymocytes
and lymphoma cells. We further demonstrated that
TCF-1 directly repressed LEF-1 expression in early
thymocytes and that conditional inactivation of Lef1
greatly delayed or prevented T cell malignancy in
Tcf7/ mice. In human T-ALLs, an early thymic
progenitor (ETP) subtype was associated with dimin-
ished TCF7 expression, and two of the ETP-ALL
cases harbored TCF7 gene deletions. We also
showed that TCF-1 and LEF-1 were dispensable for
T cell lineage commitment but instead were required
for early thymocytes to mature beyond the CD4
CD8 stage. TCF-1 thus has dual roles, i.e., acting
cooperatively with LEF-1 to promote thymocyte
maturation while restraining LEF-1 expression to
prevent malignant transformation of developing
thymocytes.
INTRODUCTION
Hematopoietic progenitors seed the thymus to initiate the T cell
differentiation program. The development of ab T cells follows
sequential maturation stages, starting from immature thymo-
cytes that are double negative (DN) for CD4 and CD8 expressionI(Rothenberg and Taghon, 2005). The DN thymocytes are
further divided into four distinct subsets based on CD25 and
CD44 expression, and these are CD25CD44+ DN1, CD25+
CD44+ DN2, CD25+CD44 DN3, and CD25CD44 DN4 cells.
The c-Kit+ DN1 cells, defined as the most immature early thymic
progenitors (ETPs) (Bhandoola and Sambandam, 2006), give rise
to DN2 cells, a process known as T cell specification (Rothen-
berg and Taghon, 2005). Whereas ETP and DN2 thymocytes
retain multilineage potentials, DN3 cells are completely com-
mitted to T lineage, with the T cell receptor (TCR) b (Tcrb) gene
locus rearranged. During b-selection, DN3 thymocytes with
productive TCRb rearrangements receive survival and prolifera-
tive signals and mature into the DN4 stage (Rothenberg et al.,
2008). DN4 thymocytes then develop sequentially through
CD8+ immature single-positive (ISP) and CD4+CD8+ double-
positive (DP) stages. After vigorous selection processes, the
DP thymocytes differentiate into either CD4+ or CD8+ single-
positive T cells.
The stage-wise T cell development is guided by a large
number of transcription factors with essential and recurrent roles
(Rothenberg et al., 2008). Among these, the Wnt pathway
effector transcription factors, T cell factor 1 (TCF-1), and
lymphoid enhancer-binding factor (LEF-1), encoded by Tcf7
and Lef1, respectively, have been known to be critical for
production of T cells (Staal and Sen, 2008; Xue and Zhao,
2012). TCF-1-deficient mice show a severe reduction in thymo-
cyte numbers (Verbeek et al., 1995), with young Tcf7/ mice
exhibiting incomplete blocks of T cell development at the DN1,
DN3, and ISP stages (Schilham et al., 1998). On the other
hand, LEF-1-null mice have no apparent abnormalities in T cell
development (Okamura et al., 1998). In a fetal thymic organ
culture study, thymocytes that are deficient for LEF-1 and hypo-
morphic for TCF-1 are completely arrested at the ISP stage
(Okamura et al., 1998). These observations suggest that TCF-1
and LEF-1 have overlapping functions during thymocytemmunity 37, 813–826, November 16, 2012 ª2012 Elsevier Inc. 813
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effect. Notch signaling is an indispensable positive regulator
of T cell lineage specification, commitment, and b-selection
(Yashiro-Ohtani et al., 2010). Two recent studies demonstrated
that TCF-1 is sharply induced upon activation of the Notch
signaling in hematopoietic progenitors (Germar et al., 2011;
Weber et al., 2011). Importantly, forced expression of TCF-1 is
sufficient to specify a T cell fate in the absence of active Notch
signaling (Weber et al., 2011).
Developing T cells are susceptible to malignant transforma-
tion, because of their highly proliferative nature at several
developmental stages and DNA double-strand breaks gener-
ated during TCR locus rearrangements. Juxtaposition of genes
encoding oncogenic transcription factors next to the strong
TCR enhancers and promoters is a known leading cause of
human T cell leukemia and lymphoma (Aifantis et al., 2008;
Grabher et al., 2006). Deregulation of key pathways that are
critical for T cell development also constitutes either initiating
or promoting events that ultimately lead to malignant transfor-
mation of thymocytes. For example, forced expression of domi-
nant active forms of Notch1 was first demonstrated in mouse
models to be causative of highly aggressive immature T cell
malignancy (Allman et al., 2001). Subsequently, somatic acti-
vating mutations in the NOTCH1 gene were found in more than
50% human T cell acute lymphoblastic leukemia (T-ALL) cases
(Weng et al., 2004).
Aberrant activation of the Wnt-b-catenin pathway has been
found in various cancers including hematological malignancy
(Reya and Clevers, 2005). b-catenin protein is posttranslationally
modulated byWntmorphogen-initiated signaling. Glycogen syn-
thase kinase-3b (GSK-3b), a component of a cytosolic multimo-
lecular ‘‘destruction complex,’’ phosphorylates four conserved
serine and threonine residues in the N terminus of b-catenin,
marking it for proteosome-mediated degradation. Wnt-elicited
signaling cascades ultimately leads to inactivation of GSK-3b
and hence b-catenin stabilization (Xue and Zhao, 2012). The
accumulated b-catenin then translocates into the nucleus where
it interacts with the TCF-LEF transcription factors and a myriad
of other factors to modulate gene expression (Mosimann et al.,
2009). Although a causative involvement of activated Wnt-b-cat-
enin pathway in human T cell malignancy has not been estab-
lished thus far, forced expression of stabilized forms of b-catenin
in mice results in T cell malignancy that resembles T-ALL (Guo
et al., 2007). However, it remains unknown whether TCF-1 and
LEF-1 are involved in malignant transformation of developing
thymocytes.
Herewe have reported a surprising finding that Tcf7/ thymo-
cytes are highly susceptible to malignant transformation, indi-
cating a role of TCF-1 in tumor suppression. Mechanistically,
the tumor-suppressive effect of TCF-1 was mediated by directly
restraining the expression of LEF-1, revealing an unexpected
interplay between TCF-1 and LEF-1, beyond their redundant
functions in promoting thymocyte maturation. This notion was
further supported by in vivo evidence that elimination of LEF-1
greatly delayed or prevented malignant transformation of TCF-
1-deficient thymocytes. In-depth analyses of TCF-1 and LEF-1
double-deficient thymocytes revealed that TCF-1 and LEF-1
were not required for T cell specification or commitment but
were rather indispensable for b-selection andmaturation beyond814 Immunity 37, 813–826, November 16, 2012 ª2012 Elsevier Inc.the DN4 stage. These observations elucidate dual roles of
TCF-1, i.e., acting cooperatively with LEF-1 to promote b-selec-
tion at the DN3 stage and restraining LEF-1 expression to
prevent transformation of early thymocytes.
RESULTS
TCF-1-Deficient Mice Develop T Cell Lymphoblastic
Lymphomas
During our studies on the role of TCF-1 in regulatingmature T cell
responses (Zhou et al., 2010), we found that Tcf7/ mice
developed progressive illness involving hunched posture and
lethargy, with palpably enlarged spleen and peripheral lymph
nodes, and all mice succumbed to death (Figure 1A). Necropsy
revealed enlarged thymus and loss of its distinctive bilobed
morphology. Histological analysis confirmed complete efface-
ment of the cortical-medullary structure in the thymus and
normal structure in the spleen by monotonous lymphoblastic
cells (Figure 1B). To determine the origin of the neoplastic cells,
we performed immunophenotypic analysis of lymphoma
cells and found that they were negative for B220, CD19,
NK1.1, and myeloid lineage markers but positive for proteins
characteristic of T cell lineage cells. Of 39 individual lymphomas
analyzed, 31 (79.4%) were CD3+TCRb+ and among these, 16
were CD25+CD44 (corresponding to the DN3 stage), 11 were
CD25CD44 (DN4 stage), and 4 were a mixture of both
populations (Figure 1C). Interestingly, some of these lymphomas
exhibited aberrant expression of CD8, reminiscent of ISP
cells (Figure 1C). On the other hand, 8 out of 39 lymphomas
(20.6%) were negative for CD3 and TCRb but were CD4hi
and expressed varied amounts of CD8 (Figure 1D), loosely
corresponding to the CD4+CD8+ DP stage. These data indicate
that the neoplastic cells in Tcf7/ mice are derived from T cell
origin.
We further analyzed the clonality of TCRb+ lymphomas. Six of
eight independent lymphoma lines expressed a known TCRb
subtype in the mouse TCRb screen panel (Figure S1A available
online), suggesting that Tcf7/ T cell lymphomas could arise
from a single clone. The lymphomas were propagated upon
transplantation into C57BL/6 recipients without irradiation pre-
conditioning, demonstrating their malignant properties (Fig-
ure S1B). Based on the ‘‘Bethesda proposals for classification
of lymphoid neoplasms in mice’’ (Morse et al., 2002), Tcf7/
lymphomas can thus be defined as precursor T cell neoplasm,
resembling human T-ALL.
During T cell development, TCR loci undergo extensive
recombination events, and improper repair of the resulting
DNA double-strand breaks may lead to chromosomal abnormal-
ities that ultimately result in thymocyte malignancy. To address
this possibility, we crossed Tcf7/ mice with a Rag1/ strain.
The Tcf7/Rag1/ mice still developed lymphomas (Fig-
ure S1C), indicating that Tcf7/ lymphomas are independent
of Rag activity. This is in contrast to the thymic lymphomas found
in mice expressing stabilized b-catenin, where deletion of Rag2
prevented thymocyte transformation (Guo et al., 2007). Quantita-
tive cytogenetics revealed that five of six lymphomas were
diploid with only rare tetraploid cells (Figure S1D), suggesting
that chromosome instability may not be amajor cause of Tcf7/
thymocyte transformation.
Figure 1. Tcf7–/– Mice Develop T Cell Lymphoblastic Lymphomas
(A) Kaplan-Meier survival curve of Tcf7/mice. A cohort of Tcf7/mice (n = 24) along withWT and Tcf7+/ littermates (each > 10) were monitored for 40 weeks.
None of the control mice developed lymphomas (not depicted).
(B) Histological analysis of thymi and spleens fromWT or Tcf7/mice that developed lymphomas. Representative images are shown (black scale bar represents
100 mm). All Tcf7/mice with lymphomas exhibited similar diffuse infiltration and effacement of normal tissue structure by neoplastic cells. Insets in right panels
show neoplastic cells on higher magnification (yellow scale bar represents 20 mm).
(C and D) Immunophenotypic analysis of Tcf7/ lymphomas. Lymphoma cells were harvested and surface stained. Initial gating was on lymphoma blasts based
on their increased forward and side scatters, and surface markers were analyzed on the blasts. Representative contour plots for 31 DN lymphomas (C) or 8 DP
lymphomas (D) are shown. Marked in red on top of the contour plots is the frequency of each immunophenotype observed.
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Thymocytes and Tcf7–/– T Cell Lymphomas
Because Tcf7/ T cell lymphomas can develop independent of
Rag activity or gain or loss of chromosomes, we hypothesizedIthat perturbations in gene expression resulting from loss of
TCF-1 is a leading cause of malignant transformation of Tcf7/
thymocytes. We thus performed transcriptomic analysis of WT
and premalignant Tcf7/ DN3 cells (each in triplicate) alongmmunity 37, 813–826, November 16, 2012 ª2012 Elsevier Inc. 815
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reasoned that gene expression alterations that were causative
in tumorigenesis should be TCF-1 dependent and thus first de-
tected in Tcf7/ premalignant cells and that such alterations
should be further exaggerated in lymphoma cells. By a direct
comparison of WT and Tcf7/ DN3 thymocytes, we identified
138 unique genes that were upregulated R1.5-fold (p < 0.05)
in Tcf7/ cells and grouped these genes as ‘‘TCF-1-repressed
gene set.’’ We then used this gene set in GSEA (Gene Set Enrich-
ment Analysis) to compare lymphomas with DN3 cells. This
analysis revealed that 63 TCF-1-repressed geneswere positively
enriched in lymphomas (Figures 2A and 2B). Functional annota-
tion with DAVID bioinformatic resources identified several tran-
scription regulators including inhibitor of DNA binding 2 (Id2)
and LEF-1 (Figure S2A).
Id2 is a natural dominant-negative regulator of E proteins
including E2A (Kee, 2009), and deficiency in E2A or transgenic
expression of Id2 results in high incidence of T cell lymphomas
(Bain et al., 1997; Morrow et al., 1999; Yan et al., 1997). The
elevated LEF-1 expression in Tcf7/ T cell lymphomas
appeared counter-intuitive given the known redundant roles of
TCF-1 and LEF-1 in promoting thymocyte maturation. However,
LEF-1 has been reported to have tumorigenic effects as indi-
cated by the fact that its ectopic expression causes B lympho-
blastic and acute myeloid leukemia (Petropoulos et al., 2008).
Increased Id2 and Lef1 transcripts were validated in Tcf7/
DN3 thymocytes and lymphoma cells (Figure 2C). Interestingly,
Id2 and Lef1 expression was also elevated in Tcf7/ DN4 and
preselect TCRbloCD69 DP thymocytes (Figures S2B and
S2C), suggesting that TCF-1 is required for restrained expres-
sion of Id2 and LEF-1 throughout early T cell developmental
stages. Id2 protein is downregulated after the DN3 stage and
below detection sensitivity in DN thymocytes (David-Fung
et al., 2009); however, Id2 was detected in all Tcf7/
lymphomas tested, although the expression amounts varied
(Figure 2D, lanes 1–4). LEF-1 was detected as a 57 kDa full-
length and a 38 kDa short isoform in WT DN thymocytes, and
its expression was drastically elevated in all the lymphoma cells
(Figure 2D). Taken together, these data indicate that loss of
TCF-1 causes abnormal upregulation of Id2 and LEF-1, which
may lead to thymocyte transformation.
A Role of TCF-1 in Human T-ALLs
In human T-ALLs, a subtype that phenotypically resembles ETPs
(ETP-ALLs) comprises approximately 15% of T-ALL cases and
associates with poor prognosis (Coustan-Smith et al., 2009).
The ETP-ALL cases also show increased genomic instability,
harboring distinct sets of activating and inactivating mutations
from the conventional non-ETP T-ALLs (Zhang et al., 2012). To
determine whether the Tcf7/ T cell lymphomas bear resem-
blance to human disease on a molecular level, we compared
gene expression between Tcf7/ lymphomas and WT DN3
thymocytes and identified 299 downregulated and 309 upregu-
lated genes in Tcf7/ lymphomas. We then analyzed these
two gene sets by performing GSEA on the expression profiles
of 12 ETP-ALLs and 40 non-ETP T-ALLs in a St Jude Children’s
Research Hospital cohort (GEO accession GSE28703) (Zhang
et al., 2012). Thirty-nine of the downregulated genes in Tcf7/
lymphomas were negatively enriched in the ETP-ALL cases816 Immunity 37, 813–826, November 16, 2012 ª2012 Elsevier Inc.(Figure 3A), and among these, TCF7 expression was the most
diminished in ETP-ALLs compared with non-ETP T-ALL cases
(Figure 3B). On the other hand, 78 of the upregulated genes in
Tcf7/ lymphomas were positively enriched in ETP-ALL cases,
including ID2 (Figure S3). These analyses reveal that the murine
T cell lymphomas caused by TCF-1 deficiency share common
deregulated genes with human diseases, and that most impor-
tantly, ETP-ALL cases are consistently associated with
decreased expression of TCF-1.
In different sets of experiments, 12 of 19 ETP-ALL samples
were analyzed with whole-genome sequencing, but no muta-
tions were found in the TCF7 locus (Zhang et al., 2012). However,
genomic single-nucleotide polymorphism array analysis of 15 of
the 19 samples revealed that 2 ETP-ALL cases showed single
copy loss of the region flanking the TCF7 gene on chromosome
5q (Figure 3C). This observation suggests that loss of heterozy-
gosity in the TCF7 genes might be an initiation and/or promoting
genetic event in transformation of human thymocytes.
TCF-1 Directly Restrains LEF-1 Expression in Early
Thymocytes
Both TCF-1 and LEF-1 can interact with b-catenin coactivator or
TLE/GRG (transducin-like enhancer/Groucho-related gene)
corepressors to achieve balanced expression of their target
genes (Hoverter and Waterman, 2008; Xue and Zhao, 2012).
To investigate whether TCF-1 directly modulates the expression
of LEF-1 and/or Id2, we stimulated sorted DN3 thymocytes with
6-bromo-substituted indirubin-acetoxime (BIO), a specific inhib-
itor of GSK-3b, to stabilize b-catenin (Zhou et al., 2010). Whereas
its inactive analog N-methylated BIO (MetBIO) had little effect,
BIO treatment induced the expression of Axin2, a known target
gene of the Wnt-b-catenin pathway (Figure 4A). Interestingly,
stimulation of DN3 thymocytes with BIO repressed the ex-
pression of both Id2 and Lef1 (Figure 4A). Because inhibition of
GSK-3b may have off-target effects, we introduced a WT or
mutant form of b-catenin into DN thymocytes by retroviral
transduction. The mutant b-catenin is constitutively activated
and stabilized as a result of an internal deletion of the GSK-3b
phosphorylation sites (Tetsu and McCormick, 1999). Although
WT b-catenin did not show an apparent effect compared with
an empty vector, the mutant b-catenin induced Axin2 and
repressed the expression of both Id2 and Lef1 in DN3 thymo-
cytes (Figure 4B), highlighting a specific effect mediated by
b-catenin activation. These observations are consistent with
the current understanding that b-catenin can actively repress
gene expression (Hoverter and Waterman, 2008).
To determine whether the Id2 and Lef1 loci are directly modu-
lated by TCF-1, we scanned 15 kb regulatory regions (–10 kb
to +5 kb) flanking the transcription initiation sites of both genes
for consensus TCF binding motif, 50-TCAAAG. We then per-
formed chromatin immunoprecipitation (ChIP) with a TCF-1
antibody on DN3 thymocytes. Survey of the cross-species-
conserved motifs by quantitative polymerase chain reaction
(PCR) revealed enriched binding of TCF-1 at a cluster of three
motifs located around –4.4 kb in the Lef1 locus (designated as
TCF1 binding cluster or TBC) (Figures 4C and 4D). Direct binding
of TCF-1 was not found within the 15 kb region in the Id2 gene,
suggesting that Id2 may be indirectly regulated by TCF-1 or
alternatively regulated through more distal elements. We also
Figure 2. Aberrant Upregulation of Id2 and LEF-1 in Tcf7–/– Thymocytes and T Cell Lymphomas
(A) Assessment of TCF-1-repressed genes in Tcf7/ lymphomas byGSEA. The gene set of TCF-1-repressed geneswas analyzed byGSEA against rank-ordered
data set of Tcf7/ lymphomas versus WT control (Ctrl) and Tcf7/ DN3 cells. The enrichment plot is shown, with genes at the leading edge highlighted in a red
rectangle.
(B) Heatmap of the 63 genes in the leading edge as in (A). Id2, Lef1, and Dtx1 are marked by green arrows. For functional annotation of these genes, see
Figure S2A.
(C) Validation of increased Id2 and Lef1 transcripts in Tcf7/DN3 thymocytes and lymphomas. Data are means ± SD (n = 4 for control and Tcf7/ and n = 12 for
lymphomas). *p < 0.05; ***p < 0.001 compared with control DN3 cells.
(D) Aberrant expression of Id2 and LEF-1 proteins in Tcf7/ T cell lymphomas. Cell lysates were isolated from control DN thymocytes, independent lines of
lymphomas from Tcf7/ or Tcf7/Id2/ mice. The lysates were immunoblotted for Id2 and LEF-1 with b-actin as an equal loading control.
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Figure 3. Molecular Resemblance of Tcf7–/–
Lymphomas to Human ETP-ALLs
(A andB)GSEAondownregulatedgenes inTcf7/
lymphomas. The downregulated gene set was run
against the gene expression profiles of 12 ETP-
ALLs and 40 non-ETP T-ALLs. The enrichment plot
is shown in (A), with the red rectangle marking
negatively enriched genes in ETP-ALLs. Heatmap
(B) of the top 10most differentially regulated genes
between ETP-ALLs and non-ETP T-ALLs.
(C) Identification of monoallelic TCF7 deletion in
ETP-ALL cases. Genomic DNA from 15 ETP-ALL
samples was hybridized to the Affymetrix SNP6
GeneChip Human Mapping Arrays. The signal
strength was manually curated for the TCF7 and
flanking gene loci on chromosome 5q and shown
in the heatmap. The color-coded scale of signal
strength is displayed below the heatmap. The
TCF7 locus was highlighted in green rectangle.
The green vertical arrows mark the two ETP-ALL
cases that harbor monoallelic loss of TCF7. The
SNP6 microarray data were previously deposited
in the dbGaP database under the accession
number phs000340.v1.p1.
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direct binding of TCF-1 to the TBC in the Lef1 genes in prese-
lected DP thymocytes (Figures S4A and S4B).
To investigate whether the TBC confers repression of Lef1
expression, we performed reporter assays by using self-inacti-
vating retroviruses to deliver reporter genes and their respective
control elements into primary thymocytes (Rosenbauer et al.,
2006). The retrovirus contains two reporters: the GFP reporter
is driven by phosphoglycerate kinase promoter and serves as
a marker for selection of virally infected cells, and the Thy1.1
reporter is driven by the murine Lef1 promoter (–333 to +81 bp)
(Figure 4E). Upstream of the Lef1 promoter, we inserted either
the WT TBC segment (350 bp, –4637 to –4289) or a mutant818 Immunity 37, 813–826, November 16, 2012 ª2012 Elsevier Inc.TBC where all three TCF-1 binding motifs
were mutated (Figure 4E). The Lef1
promoter led to expression of Thy1.1
in >50% GFP+ DN3 thymocytes, and
insertion of the WT TBC greatly dimin-
ished the frequency of cells expressing
Thy1.1 and the amount of Thy1.1 protein
as measured by mean fluorescent inten-
sity (MFI) (Figure 4F). Importantly, muta-
tion of TCF-1 binding motifs in the TBC
partly relieved the repressive effect, re-
sulting in increased frequency of Thy1.1+
cells as well as Thy1.1 protein expression
(Figure 4F). These data thus strongly
support that TCF1 directly restrains
LEF-1 expression in early thymocytes.
TCF-1-Mediated Repression
of Id2 and LEF-1 Suppresses
T Cell Malignancy
Based on the observation that TCF-1
utilized b-catenin to repress LEF-1 andId2 expression in early thymocytes, we next investigatedwhether
deregulation of Id2 or LEF-1 led to transformation of Tcf7/
thymocytes. By crossing Tcf7/ mice to an Id2/ background
(Yokota et al., 1999), we found that elimination of Id2 in Tcf7/
mice delayed the onset of lymphomas and reduced the pene-
trance rate of the disease at 40 weeks (Figure 5A). Interestingly,
the T cell lymphomas in Tcf7/Id2/ mice retained abnormal
upregulation of LEF-1 (Figure 2D, lanes 5 and 6), suggesting
that abnormal upregulation of LEF-1 may have contributed to
transformation of Tcf7/Id2/ cells.
Germline disruption of both TCF-1 and LEF-1 was embryonic
lethal, so we conditionally targeted the Lef1 gene by inserting
two LoxP sites to flank exons 7 and 8, which encode the DNA
Figure 4. TCF-1-Mediated Repression of Id2 and LEF-1 in Early Thymocytes
(A) Inhibition of GSK-3b repressed Id2 and LEF-1 expression. Sorted DN3 thymocytes were treated with MetBIO or BIO for 6 hr, and indicated transcripts were
quantitatively determined.
(B) Activation of b-catenin-repressed Id2 and LEF-1. Lin DN thymocytes were cultured on monolayer of OP9-DL1 cells overnight and then transduced with
retrovirus expressingGFP only (pMIG), WT, or mutant form of b-catenin. After 24 hr, GFP+ DN3 thymocytes were sorted andmeasured for expression of indicated
genes.
For (A) and (B), data are means ± SD from three independent experiments. **p < 0.01; ***p < 0.001.
(C) Schematic showing conserved TCF-1 binding motifs in the Lef1 locus. Shown on the top is the cross-species conservation of the Lef1 regulatory sequences
at –10 to +5 kb region based on the UCSC genome browser. Conserved TCF-1 binding motifs and their relative locations are marked. Also see Figure S4C for
sequence alignments at the –4.4 kb TCF-1 binding cluster (TBC).
(D) Direct binding of TCF-1 to the Lef1 locus. ChIP was performed on DN3 thymocytes, and all conserved motifs in (C) were assessed for enriched TCF-1 binding.
The Axin2 T2-T3 regulatory region was used as a positive control and theGapdh gene body as a negative control. Data are pooled results from two independent
experiments with each motif measured in triplicate.
(E) Schematics showing the retroviral reporter constructs. The retrovirus is self-inactivating due to mutations in its long terminal repeats (SIN). PGK, phos-
phoglycerate kinase promoter; LefPro, murine Lef1 promoter. Arrows denote the transcription initiation sites and orientations.
(F) TheTCF-1bindingcluster confersLEF-1 repression. LinDNthymocyteswere infectedwith the reporter retrovirusesas in (B). Theexpressionof Thy1.1 reporter,
in terms of frequency andMFI, was determined on GFP+ DN3 thymocytes. Similar results were obtained for other DN subsets (not shown). Gating of Thy1.1+ cells
was based on background staining in corresponding GFP subset. Data are representative of two independent experiments with similar results (n = 4).
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sion (Figure S5B), we used a Flippase transgene to remove the
neomycin-resistant gene to minimize disturbance of the native
Lef1 gene locus, and the resulting allele was designated as
Lef1-floxed allele (Lef1FL/+) (Figure S5C). To ablate LEF-1 protein
in thymocytes at early developmental stages, we used a Vav1-
Cre transgene, which initiates excision of the floxed sequences
in early hematopoietic progenitor cells (Ogilvy et al., 1999).
Western blotting confirmed efficient elimination of the LEF-1
protein in total bone marrow cells and thymocytes from Vav1-
Cre+:Lef1FL/FL mice (referred to as Lef1/) (Figure 5B). We
then used more sensitive quantitative RT-PCR to validate
complete elimination of Lef1 transcripts in DN3 thymocytes
from Lef1/ or Vav1-Cre+:Lef1FL/FLTcf7/ mice (referred to
as Lef1/Tcf7/) (Figure 5C). Lef1 transcripts were detected
at much lower quantity in hematopoietic stem cells (HSCs),
and deletion of Lef1 was complete in both Lef1/ and Lef1/
Tcf7/ HSCs (Figure 5D). TCF-1 deficiency alone substantially
diminished total as well as DN3 thymocytes (Schilham et al.,
1998; Verbeek et al., 1995). Elimination of both TCF-1 and
LEF-1 did not cause further significant reduction in total thymic
cellularity or the DN3 subset (Figures 5E and 5F), and definitiveIT cell lymphopoiesis did occur in Lef1/Tcf7/ mice (detailed
below). We have monitored a cohort of Lef1/Tcf7/ mice
along with their Tcf7/ littermates. All the Tcf7/ littermates
succumbed to T cell lymphomas by 40weeks of age. In contrast,
10 out of 13 Lef1/Tcf7/mice survived the 45-week observa-
tion period without overt signs of lymphoma formation (Fig-
ure 5G). The other three Lef1/Tcf7/ mice that died between
30 and 45 weeks were found to have enlarged thymi, and the
malignant thymocytes showed a phenotype of CD4CD8
CD3TCRb, consistent with a complete block of T cell develop-
ment at the DN stage in the absence of TCF-1 and LEF-1
(detailed below). Thus, deletion of LEF-1 greatly delayed or pre-
vented malignant transformation of Tcf7/ thymocytes.
The Involvement of Notch Signaling in Tcf7–/– T Cell
Lymphomas
Somatic activating mutations of NOTCH1 have been found in
more than 50% of all T-ALL cases (Aifantis et al., 2008; Grabher
et al., 2006) and in several mouse models of T cell lymphomas
(Lin et al., 2006; O’Neil et al., 2006). Deltex1 (encoded by
Dtx1), a known Notch target gene, exhibited increased expres-
sion in both Tcf7/ DN3 thymocytes and T cell lymphomasmmunity 37, 813–826, November 16, 2012 ª2012 Elsevier Inc. 819
Figure 5. Elimination of Id2 or LEF-1 Delayed or Prevented Malignant Transformation of Tcf7–/– Thymocytes
(A) Elimination of Id2 delayed onset of lymphomas in Tcf7/ mice. Shown are Kaplan-Meier survival curves for Tcf7/Id2/ and Tcf7/ littermates.
(B) Effective elimination of LEF-1 protein by Vav1-Cre. Cell lysates from bone marrow (BM) cells and thymocytes (Thy) of Lef1/ or control mice were
immunoblotted for LEF-1 expression.
(C) Elimination of Lef1 transcripts in DN3 thymocytes. Lef1 transcripts were measured by quantitative RT-PCR in sorted DN3 thymocytes and normalized to
Hprt1. N.D., not detectable. Similar results were obtained for DN4 cells (not shown).
(D) Elimination of Lef1 transcripts in HSCs. Bonemarrow cells were harvested and sorted for lineage-negative Sca1+c-Kit+Flt3 subset, which contains both long-
term and short-term HSCs, followed by measurements of Lef1 transcripts as in (C).
Data in (C) and (D) are means ± SD (nR 4 from 2 independent experiments).
(E) Total thymic cellularity. Data are means ± SD (n = 5).
(F) DN3 thymocyte numbers. Data are means ± SD (nR 7). ***p < 0.001. N.S., not statistically significant.
(G) Elimination of LEF-1 greatly delayed onset and partly protected Tcf7/ mice from T cell lymphomas. Shown are Kaplan-Meier survival curves for
Lef1/Tcf7/ and Tcf7/ littermate controls.
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found that Notch1 itself and other Notch target genes, including
Ptcra (encoding pre-TCRa) and Hes1, all exhibited moderately
increased expression in Tcf7/ and Lef1/Tcf7/DN3 thymo-
cytes (Figure 6A). However, the expression of Notch1 and its
other targets were not increased, but rather decreased, in
Tcf7/ lymphomas (Figure 6A), suggesting deregulation of
Notch signaling in transformed cells.820 Immunity 37, 813–826, November 16, 2012 ª2012 Elsevier Inc.It was reported that Notch1 signaling is essential for survival
of T cell lymphomas caused by E2A deficiency and that LEF-1
acts downstream of Notch1 in this context (Spaulding et al.,
2007). Because Tcf7/ thymocytes showed increased ex-
pression Notch1 and its target genes, we next investigated
whether elevated Notch signaling may induce LEF-1 expression
in early thymocytes. To this end, we treated DN thymocytes
with a g-secretase inhibitor (GSI) to block the release of
Figure 6. Notch1 in Tcf7–/– Thymocytes and T Cell Lymphomas
(A) Notch signaling wasmoderately enhanced in Tcf7/DN3 thymocytes but was not sustained after transformation. Sorted DN3 thymocytes weremeasured for
the expression ofNotch1 and its target genes, in direct comparison with Tcf7/ lymphomas. Data aremeans ± SD from three independent experiments (n = 4–8).
(B) Inhibition of g-secretase did not repress Lef1 expression in DN3 thymocytes. Lin DN thymocytes were cultured on OP9-DL1 stromal cells in the presence of
DMSO or GSI for 24 hr. DN3 thymocytes were sorted and measured for indicated transcripts. Data are means ± SD from two independent experiments (n = 4).
(C) Forced expression of ICN or DN-MAML did not detectably affect Lef1 expression. Lin DN thymocytes were infected with pMIG retrovirus or that expressing
either ICN or DN-MAML. The GFP+ DN3 cells were sorted 24 hr postinfection and measured for indicated transcripts. Data are means ± SD from three inde-
pendent experiments (n = 6).
For (A)–(C), *p < 0.05; ***p < 0.001; N.S., not statistically significant.
(D) Cleaved Notch1 was expressed in Tcf7/ but not Lef1/Tcf7/ T cell lymphomas. Cell lysates from the lymphomas or total thymocytes were immuno-
blotted to detect cleaved Notch1, with b-actin as a loading control.
(E) Notch1 was mutated in the PEST domain in Tcf7/ T cell lymphomas. Notch1 cDNA was amplified from thymocytes or lymphomas and sequenced for
marked regions. For Notch1, the first nucleotide in its open reading frame was designated as 1, and the coding sequence in exon 34 is within 6151 to 7597.
Mutation sites were determined based on this numbering.
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Dual Roles of TCF-1 in Early Thymocytestranscriptionally active intracellular domain of Notch1 (ICN). GSI
treatment effectively diminished the expression of Dtx1 and
Ptcra as expected, but did not repress Lef1 or Notch1 expres-
sion in DN3 cells (Figure 6B). We also retrovirally introduced
a dominant-negative form of the coactivator mastermind-like
(DN-MAML) into DN thymocytes to specifically disrupt the
Notch1-CSL-MAML transactivation complex (Maillard et al.,
2004). The DN-MAML led to suppression of Notch1 targets
Dtx1 and Ptcra but did not affect Lef1 or Notch1 (Figure 6C).
Conversely, forced expression of ICN in DN thymocytes
induced Dtx1 and Ptcra expression, without an apparent effect
on Lef1 or Notch1 (Figure 6C). Thus, the induction of LEF-1 by
Notch signaling appears to be more specific to selected cell
context and is not operating in T cell lineage-committed early
thymocytes.
Although the Notch signaling is deregulated in Tcf7/
lymphomas, cleaved Notch1 proteins were readily detected in
all Tcf7/ lymphomas tested, with their molecular weights being
smaller than the expected 120 kD (Figure 6D). The truncated
forms of Notch1 protein in the lymphomas suggested possible
mutations, which are frequently found in the heterodimerization
(HD) domain (coded by exons 26 and 27) and proline, glutamic
acid, serine, threonine-rich (PEST) domain (coded by exon 34)
in human T-ALLs and murine T cell lymphomas (Grabher et al.,
2006; Lin et al., 2006; O’Neil et al., 2006). Mutations in the HD
domain facilitate Notch1 cleavage by g-secretase, and muta-
tions in the PEST domain prolong Notch1 half-life (Grabher
et al., 2006). By sequencing the Notch1 cDNA, we found muta-
tions in the PEST domain in all six Tcf7/ lymphomas examined
but found no mutations in the HD domain in these samples (Fig-
ure 6E). Surprisingly, none of the three T cell lymphomas in aged
Lef1/Tcf7/mice expressed cleaved Notch1 (Figure 6D), and
none of them had Notch1 mutations in the HD or PEST domains
(Figure 6E). It is of interest to note that Notch1was notmutated in
the premalignant Tcf7/or Lef1/Tcf7/ DN3 thymocytes
(Figure 6E), although Notch1 and its target genes were upregu-
lated in these cells (Figure 6A). It is thus likely that Notch1 muta-
tions are acquired after malignant transformation of Tcf7/
thymocytes and such mutations are dispensable for transforma-
tion in the context of TCF-1 and LEF-1 deficiency.
TCF-1 and LEF-1 Are Dispensable for T Cell Lineage
Commitment but Are Required for b-Selection and
Further Maturation beyond the DN4 Stage
Our studies thus far revealed an unexpected role of TCF-1 in re-
straining LEF-1 expression to prevent thymic tumorigenesis. A
recent report demonstrated that forced expression of TCF-1 in
bone marrow progenitors is sufficient to promote T cell specifi-
cation and activate the T cell lineage differentiation program
(Weber et al., 2011). To further explore the requirement of TCF-1
and LEF-1 in the T cell developmental process, we performed
in-depth analysis of the developmental state of Lef1/Tcf7/
thymocytes. TCF-1 and LEF-1 double deficiency blocked T cell
development at the DN stage (Figure 7A), and this block was
earlier than the previously reported ISP block in fetal thymic
organ culture of TCF-1-hypomorphic LEF-1-null fetal liver cells
(Okamura et al., 1998). In some Lef1/Tcf7/ mice, thymo-
cytes that were positive for CD4 and/or CD8 could be detected
at low frequencies, but they were devoid of cell surface TCRb822 Immunity 37, 813–826, November 16, 2012 ª2012 Elsevier Inc.expression (Figure S6A), suggesting that Lef1/Tcf7/ thymo-
cytes cannotmature beyond the DN stage to acquire a functional
TCR. Consistent with this, no mature T cells were detected in the
Lef1/Tcf7/ spleens (Figure S6B). Further analysis of DN
subsets showed that TCF-1 and LEF-1 double deficiency did
not cause more severe blocks at DN1 or DN3 stages compared
with loss of TCF-1 alone (Figure 7B). Importantly, the
Lef1/Tcf7/ DN3 thymocytes expressed intracellular TCRb
at a similar frequency as control or Tcf7/ DN3 cells (Figures
7C and 7D). Furthermore, assessment of DJ and V to DJ recom-
bination at the Tcrb locus revealed that similar to Tcf7/ cells,
Lef1/Tcf7/ thymocytes contained all the expected rear-
ranged segments (Figure S7). Coupled with the observation
that deletion of LEF-1 did not further reduce DN3 cell numbers
in the context of TCF-1 deficiency (Figure 5F), our data indicate
that TCF-1 and LEF-1 are not required for generation of DN3
thymocytes and TCRb rearrangement, the definitive events for
T cell lineage commitment.
b-selection at the DN3 stage allows those with productive
TCRb rearrangements to mature to DN4 thymocytes, with the
majority of these cells expressing intracellular TCRb protein
(Rothenberg and Taghon, 2005). b-selection was not affected
by LEF-1 deficiency alone and was less efficient in Tcf7/
mice (Figures 7C and 7D). Strikingly, no increase in intracellular
TCRb+ cells was found in Lef1/Tcf7/ DN4 cells (Figures 7C
and 7D), suggesting impaired b-selection and/or pre-TCR
signaling events in the absence of both TCF-1 and LEF-1. These
data collectively indicate that whereas definitive T cell lineage
specification and commitment can occur in the absence of
TCF-1 and LEF-1, these two factors are indispensable for
b-selection and further maturation beyond the DN4 stage.
DISCUSSION
In this study, we demonstrated an unexpected interplay between
TCF-1 and LEF-1. They belong to the same TCF-LEF subfamily
of HMG box-containing transcription factors and recognize the
same 50-TCAAAG consensus sequence via their conserved
HMG DNA binding domain. Existing genetic evidence indicates
that TCF-1 and LEF-1 have cooperative roles in promoting
thymocyte maturation (Okamura et al., 1998). Our findings re-
vealed that restraint of LEF-1 by TCF-1 is critical to fulfill their
physiological function in T cell development and avoid detri-
mental transformation. In the context of colon cancer cells where
constitutively activated b-catenin is a known cause of colorectal
malignancy, the TCF-4-b-catenin complex was reported to upre-
gulate LEF-1 and TCF-1 (Hovanes et al., 2001; Roose et al.,
1999). In developing thymocytes, TCF-1 and LEF-1 are both
abundantly expressed from the DN3 stage onward, and TCF-1
utilizes b-catenin to actively repress LEF-1 expression. We
showed direct binding of TCF-1 to a –4.4 kb cis-regulatory
sequence in the Lef1 locus and further demonstrated that this
sequence was sufficient to confer repression of Lef1 expression
in primary thymocytes. Most importantly, elimination of LEF-1
greatly delayed or prevented malignant transformation of TCF-
1-deficient early thymocytes. These findings thus elucidate
a new form of genetic interaction among the TCF-LEF factors
to ensure their normal functions. Forced expression of TCF-1
in hematopoietic progenitors was recently reported to lead to
Figure 7. A Cooperative Function between
TCF-1 and LEF-1 Is Required for b-Selection
at the DN3 Stage
(A) TCF-1 and LEF-1 double deficiency arrested
T cell development at the DN stage. Lin thymo-
cytes were fractioned based on CD4 and CD8
expression.
(B) Ablation of LEF-1 did not further exacerbate
T cell developmental blocks caused by TCF-1
deficiency within the DN stage. LinCD4CD8
thymocytes were fractionated based on CD25 and
CD44 expression.
Data in (A) and (B) are representative of at least
three independent experiments with similar
results. The percentage of each subset is marked.
(C) TCF-1 and LEF-1 are required for efficient
b-selection. DN3 and DN4 thymocytes were
intracellularly stained for TCRb expression, and
the percentage of TCRb+ population is marked in
representative histograms.
(D) Cumulative frequency of intracellular TCRb+
DN3 and DN4 thymocytes. Data are means ± SD
(n = 3). *p < 0.05; **p < 0.01; and ***p < 0.001.
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secondary to activation of T cell specification program by TCF-
1, or alternatively specific to the cell context of hematopoietic
progenitors. These possibilities merit future investigations.
Transformation of Tcf7/ thymocytes involves several
genetic events. First, in addition to loss of restraint of LEF-1,
Tcf7/ thymocytes showed elevated Id2 expression. Overex-
pression of Id2 or deletion of E2A is known to cause T cell
lymphomas (Bain et al., 1997; Morrow et al., 1999; Yan et al.,Immunity 37, 813–826, N1997). Deletion of Id2 in the Tcf7/
mice indeed delayed the onset of
lymphomas. Second, PU.1 was reported
to be negatively regulated by TCF-1 in
early thymocytes through a –14 kb
regulatory element, and deletion of
this element caused T cell lymphomas
(Rosenbauer et al., 2006). Interestingly,
upregulation of PU.1 was not observed in
premalignant thymocytes or lymphomas
lacking the –14 kb element, and thus a
‘‘hit-and-run’’ mechanism has been pro-
posed for a role of PU.1 in thymocyte
transformation (Rosenbauer et al., 2006).
Deregulation of Id2 and/or PU.1 might
be causative events to the few cases of
T cell lymphomas in mice lacking both
TCF-1 and LEF-1. Lastly, improper acti-
vation of Notch signaling is considered
to promote thymocyte transformation
in cooperation with known predispos-
ing genetic alterations (Grabher et al.,
2006). Early thymocytes lacking TCF-1
or both TCF-1 and LEF-1 showed similar
amounts of increased expression of
Notch1 and its target genes; however,
they were starkly different in transforma-tion potentials, with all Tcf7/ mice succumbing to the disease
by 40 weeks and >75% of Lef1/Tcf7/mice being lymphoma
free at 45 weeks of age. Although a role of enhanced Notch
signaling cannot be entirely excluded, its contribution to trans-
formation of Tcf7/ thymocytes appears to be small compared
with aberrant upregulation of LEF-1. Because LEF-1 expression
is relatively unaffected by gain or loss of Notch1 signaling in early
thymocytes, the LEF-1 upregulation is unlikely secondary to
Notch1 activation. Additionally, no activating mutations inovember 16, 2012 ª2012 Elsevier Inc. 823
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thymocytes and even the Lef1/Tcf7/ lymphomas, suggest-
ing that acquisition of Notch1 mutations is dispensable for trans-
formation of thymocytes lacking TCF-1 or both factors. Notch1
mutations found in the PEST domain in Tcf7/ lymphomas
appear to be acquired as ‘‘addiction’’ to Notch signaling, which
may cooperate with early oncogenic hits to promote onset and/
or propagation of transformed cells. This view is in line with the
finding that common mutations found in human T-ALLs were
insufficient to induce transformation on their own but can accel-
erate K-ras-initiated leukemia (Chiang et al., 2008).
Gene expression profiling of the Tcf7/ lymphomas revealed
their molecular resemblance to the ETP subtype of human
T-ALLs. ETP-ALLs were consistently associated with decreased
expression of TCF-1 and increased expression of ID2, the
key characteristics of Tcf7/ lymphomas. Of particular interest,
2 of the 15 ETP-ALL cases had monoallelic deletion of the
TCF7 gene. These data suggest that loss of TCF-1, in forms of
diminished expression or gene deletion, could be a critical
contributing event in thymocyte transformation, adding to in-
depth understanding of etiology of human T cell malignancy. In
the context of TCF-1 deficiency, increased expression of
LEF-1 in both premalignant thymocytes and T cell lymphomas
is consistent with its reported tumorigenic potentials. Forced
expression of LEF-1 in murine bone marrow progenitors results
in B lymphoblastic and acute myeloid lymphoma in recipient
animals (Petropoulos et al., 2008). In humans, overexpression
of LEF-1 is strongly associated with B cell chronic lymphocytic
leukemia (Gutierrez et al., 2010a) and predicts unfavorable
outcome in patients with B cell ALL (B-ALL) (Ku¨hnl et al.,
2011). Paradoxically, deletion of the LEF1 gene has been
reported in B-ALLs (Mullighan et al., 2007) as well as T-ALLs
(Gutierrez et al., 2010b). There might be several possible expla-
nations for these seemingly contradictory observations. First,
many factors, such as Notch1 and Runx proteins, can function
as oncogenes as well as tumor suppressors depending on the
cellular context (Blyth et al., 2005; Lobry et al., 2011). LEF-1
could act in both capacities in different cell types. Second, in
one given cell type (for example developing T cells), the role of
LEF-1 in cancer may not be fixed but depend on other tumori-
genic genetic events. Among T-ALL cases that were previously
found to harbor LEF1 deletions, all had homozygous deletions
of the CDKN2A gene, and some of them had activating muta-
tions in NOTCH1 or mutations in the PTEN tumor suppressor
gene (Gutierrez et al., 2010b). Lastly, LEF-1 can interact with
both b-catenin coactivator and TLE-GRG corepressors. Gain
in LEF-1 expression may acquire increased interaction with
b-catenin and cause aberrant activation of its target genes,
and loss in LEF-1 expression may diminish TLE-GRG recruit-
ment and lead to improper gene derepression. Both changes
in LEF-1 could lead to similar detrimental effect in causing trans-
formation of thymocytes.
Conditional targeting of the Lef1 gene also allowed us to
further address the physiological requirements of TCF-1 and
LEF-1 in normal T cell development. Forced expression of
TCF-1 was recently reported to be sufficient to specify hemato-
poietic progenitors to T cell lineage and activate T cell-specific
gene expression program (Weber et al., 2011). Our study used
Vav1-Cre to eliminate LEF-1 expression in hematopoietic824 Immunity 37, 813–826, November 16, 2012 ª2012 Elsevier Inc.progenitors (Ogilvy et al., 1999). Coupled with germline deletion
of TCF-1, we found that in the absence of TCF-1 and LEF-1,
definitive thymopoiesis did occur, as evidenced by detection
of Tcrb rearrangements and intracellular TCRb proteins in
double-deficient DN3 and DN4 thymocytes. Accumulation of
DN1 and paucity of the DN2 subset were evident in TCF-1
deficiency alone (Goux et al., 2005), and these phenotypes
were not further exacerbated by deletion of LEF-1. Thus,
TCF-1 and LEF-1 are not required for T cell specification and
commitment, although both processes may have proceeded
with diminished efficiency in the absence of these factors.
The expression pattern of TCF-1 and LEF-1 is consistent with
this conclusion. Although both TCF-1 and LEF-1were expressed
at low quantity at the DN1 or ETP stage, TCF-1 is upregulated
at the DN2 and LEF-1 expression showed sharp increase at
the DN3 stage (David-Fung et al., 2009). Both factors are
maintained at high expression levels from DN3 stage onward,
and this is also in line with the critical requirements of TCF-1
and LEF-1 in b-selection and maturation beyond the DN4 stage.
In summary, this study has revealed dual roles of TCF-1 in
developing thymocytes. It cooperates with LEF-1 to promote
b-selection and further thymocyte maturation. At the same
time, the LEF-1 expression level must be kept in check by
TCF-1 to prevent malignant transformation of early thymocytes.
These findings highlight a pivotal interplay among transcription




Tcf7/ and Id2/ mice were previously described (Verbeek et al., 1995;
Yokota et al., 1999). Rag1/, Vav1-Cre transgenic, Flippase transgenic
mice were from the Jackson Laboratory. Generation of Lef1-floxed mice
was detailed in the Supplemental Experimental Procedures. All mouse exper-
iments were performed under protocols approved by the Institutional Animal
Use and Care Committee of the University of Iowa.
Microarray and Bioinformatics Analysis
Total RNA was extracted from sorted WT or Tcf7/ DN3 thymocytes and
primary lymphoma cells, and GeneChip Mouse GENE 1.0 ST arrays (Affyme-
trix) were used to probe global gene expression changes (Zhou et al., 2010).
Statistical Analysis
For monitoring primary lymphoma formation in Tcf7/mice or mice that were
double deficient for TCF-1 and Rag1, TCF-1 and Id2, or TCF-1 and LEF-1,
all death events were recorded and analyzed with the Statview5.0 software
(SAS Institute Inc). The Kaplan-Meier survival curves were generated with
the program, and statistical significance was assessed by log-rank test. For
comparison of gene expression and b-selection among mice of different
genotypes, Student’s t test was used for statistical analysis.
ACCESSION NUMBERS
The microarray data are available in the Gene Expression Omnibus (GEO)
database (http://www.ncbi.nlm.nih.gov/gds) under the accession number
GSE33292.
SUPPLEMENTAL INFORMATION
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Experimental Procedures, and seven figures and can be found with this article
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